Background: Human cellular repressor of E1A-stimulated genes (CREG) is a secreted glycoprotein that attenuates angiotensin II-induced hypertension, alleviates myocardial fibrosis, and improves heart function. However, the role of CREG in high-salt (HS) diet-induced hypertensive nephropathy is unclear. Methods: To determine the effects and molecular mechanisms of CREG in HS diet-induced hypertensive nephropathy, we established a hypertensive nephropathy animal model in Dahl salt-sensitive (SS) rats fed a HS diet (8% NaCl, n = 20) for 8 weeks. At week 4 of HS loading, these rats were administered recombinant CREG (reCREG; 35 µg/kg·day, n = 5) and saline (n = 5) via subcutaneously implanted pumps and were also administered the vasodilator hydralazine (20 mg/kg·day, n = 5) in drinking water. We used hematoxylin and eosin staining, Masson’s trichrome staining, immunohistochemical labeling, western blotting, RT-PCR, and Tunel staining to determine the signaling pathways of CREG in HS diet-induced hypertensive nephropathy. Results: After 8 weeks of HS intake, the Dahl SS rats developed renal dysfunction and severe renal fibrosis associated with reductions of 78 and 67% in CREG expression, respectively, at both mRNA and protein levels in the kidney. Administration of reCREG improved renal function and relieved renal fibrosis. Administration of CREG also inhibited monocyte infiltration and reduced apoptosis in the kidney cells. CREG overexpression upregulated forkhead box P1 expression and inhibited the transforming growth factor-β1 signaling pathway. Conclusion: Our study shows that CREG protected the kidney against HS-diet-induced renal damage and provides new insights into the mechanisms underlying kidney injury.

Keywords:
Cellular repressor of E1A-stimulated genes, Renal fibrosis, High-salt-induced hypertension, Transforming growth factor-β1, Forkhead box P1
1.
Peixoto AJ. Acute Severe Hypertension.
N Engl J Med
. 2019 Nov;381(19):1843–52.
2.
Vettoretti S, Caldiroli L, Zanoni F, Azzini V, Villarini A, Meazza R, et al. Patients with Hypertensive Nephropathy and Chronic Kidney Disease Might Not Benefit from Strict Blood Pressure Control.
Kidney Blood Press Res
. 2018;43(6):1706–15.
3.
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.
Hypertension
. 2009 Sep;54(3):475–81.
4.
Galletti F, Barbato A; MINISAL-SIIA Study Group. Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program.
J Hum Hypertens
. 2016 Nov;30(11):703–8.
5.
Bihorac A, Tezcan H, Ozener C, Oktay A, Akoglu E. Association between salt sensitivity and target organ damage in essential hypertension.
Am J Hypertens
. 2000 Aug;13(8):864–72.
6.
Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension.
Lancet
. 1997 Dec;350(9093):1734–7.
7.
Veal E, Eisenstein M, Tseng ZH, Gill G. A cellular repressor of E1A-stimulated genes that inhibits activation by E2F.
Mol Cell Biol
. 1998 Sep;18(9):5032–41.
8.
Veal E, Groisman R, Eisenstein M, Gill G. The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells.
Oncogene
. 2000 Apr;19(17):2120–8.
9.
Ghobrial G, Araujo L, Jinwala F, Li S, Lee LY. The Structure and Biological Function of CREG.
Front Cell Dev Biol
. 2018 Oct;6:136.
10.
Li Y, Liu Y, Tian X, Zhang Y, Song H, Liu M, et al. Cellular Repressor of E1A-Stimulated Genes Is a Critical Determinant of Vascular Remodeling in Response to Angiotensin II.
Arterioscler Thromb Vasc Biol
. 2017 Mar;37(3):485–94.
11.
Yan CH, Li Y, Tian XX, Zhu N, Song HX, Zhang J, et al. CREG1 ameliorates myocardial fibrosis associated with autophagy activation and Rab7 expression.
Biochim Biophys Acta
. 2015 Feb;1852(2):353–64.
12.
Kosaka S, Pelisch N, Rahman M, Nakano D, Hitomi H, Kobori H, et al. Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.
J Pharmacol Sci
. 2013;121(2):95–102.
13.
Liu J, Zhuang T, Pi J, Chen X, Zhang Q, Li Y, et al. Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1-Endothelin-1 Signal Pathway.
Circulation
. 2019 Aug;140(8):665–80.
14.
Kanter JE. FOXP1: A Gatekeeper of Endothelial Cell Inflammation.
Circ Res
. 2019 Aug;125(6):606–8.
15.
Song H, Yan C, Tian X, Zhu N, Li Y, Liu D, et al. CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis.
Biochim Biophys Acta Mol Basis Dis
. 2017 Aug;1863(8):1893–903.
16.
Sterzel RB, Luft FC, Gao Y, Schnermann J, Briggs JP, Ganten D, et al. Renal disease and the development of hypertension in salt-sensitive Dahl rats.
Kidney Int
. 1988 Jun;33(6):1119–29.
17.
Rapp JP. Dahl salt-susceptible and salt-resistant rats. A review.
Hypertension
. 1982 Nov-Dec;4(6):753–63.
18.
Shehata MF. Genetic and dietary salt contributors to insulin resistance in Dahl salt-sensitive (S) rats.
Cardiovasc Diabetol
. 2008 Apr;7(1):7.
19.
Cao Q, Harris DC, Wang Y. Macrophages in kidney injury, inflammation, and fibrosis.
Physiology (Bethesda)
. 2015 May;30(3):183–94.
20.
Hye Khan MA, Neckár J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, et al. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat.
Hypertension
. 2013 Nov;62(5):905–13.
21.
Wei SY, Wang YX, Zhang QF, Zhao SL, Diao TT, Li JS, et al. Multiple Mechanisms are Involved in Salt-Sensitive Hypertension-Induced Renal Injury and Interstitial Fibrosis.
Sci Rep
. 2017 Apr;7(1):45952.
22.
Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury.
Nephrol Dial Transplant
. 2008 Mar;23(3):842–52.
23.
Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, et al. Distinct macrophage phenotypes contribute to kidney injury and repair.
J Am Soc Nephrol
. 2011 Feb;22(2):317–26.
24.
Karlsen FM, Andersen CB, Leyssac PP, Holstein-Rathlou NH. Dynamic autoregulation and renal injury in Dahl rats.
Hypertension
. 1997 Oct;30(4):975–83.
25.
Loeffler I, Wolf G. Transforming growth factor-β and the progression of renal disease.
Nephrol Dial Transplant
. 2014 Feb;29 Suppl 1:i37–45.
26.
Casalena G, Daehn I, Bottinger E. Transforming growth factor-β, bioenergetics, and mitochondria in renal disease.
Semin Nephrol
. 2012 May;32(3):295–303.
27.
Cohen MP, Sharma K, Guo J, Eltayeb BO, Ziyadeh FN. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
Exp Nephrol
. 1998 May-Jun;6(3):226–33.
28.
Wong CK, Falkenham A, Myers T, Légaré JF. Connective tissue growth factor expression after angiotensin II exposure is dependent on transforming growth factor-β signaling via the canonical Smad-dependent pathway in hypertensive induced myocardial fibrosis.
J Renin Angiotensin Aldosterone Syst
. 2018 Jan-Mar;19(1):1470320318759358.
29.
Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice.
Am J Physiol Renal Physiol
. 2000 Apr;278(4):F628–34.
30.
García-Sánchez O, López-Hernández FJ, López-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease.
Kidney Int
. 2010 Jun;77(11):950–5.
31.
Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats.
Am J Physiol Regul Integr Comp Physiol
. 2002 Sep;283(3):R757–67.
32.
Murphy SR, Dahly-Vernon AJ, Dunn KM, Chen CC, Ledbetter SR, Williams JM, et al. Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.
Am J Physiol Regul Integr Comp Physiol
. 2012 Jul;303(1):R57–69.
33.
Xu L, Liu JM, Chen LY. CREG, a new regulator of ERK1/2 in cardiac hypertrophy.
J Hypertens
. 2004 Aug;22(8):1579–87.
34.
Benayoun BA, Caburet S, Veitia RA. Forkhead transcription factors: key players in health and disease.
Trends Genet
. 2011 Jun;27(6):224–32.
35.
Hu T, Yamagishi H, Maeda J, McAnally J, Yamagishi C, Srivastava D. Tbx1 regulates fibroblast growth factors in the anterior heart field through a reinforcing autoregulatory loop involving forkhead transcription factors.
Development
. 2004 Nov;131(21):5491–502.
36.
Friedman JR, Kaestner KH. The Foxa family of transcription factors in development and metabolism.
Cell Mol Life Sci
. 2006 Oct;63(19-20):2317–28.
37.
Ji L, Wang Q, Huang F, An T, Guo F, Zhao Y, et al. FOXO1 Overexpression Attenuates Tubulointerstitial Fibrosis and Apoptosis in Diabetic Kidneys by Ameliorating Oxidative Injury via TXNIP-TRX.
Oxid Med Cell Longev
. 2019 Mar;2019:3286928.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.